Allergan CEO Brent Saunders takes a pricing pledge: Predatory practices must end
Caught in the latest tempest over dramatic price hikes for old therapeutics, Allergan CEO Brent Saunders is swearing off the practice, vowing to maintain a fair pricing policy that could well inspire others in the business to follow suit.
This pledge includes limiting Allergan’s annual price hikes to modest single-digit increases, and Saunders says Allergan will never again jack up prices without a significant increase in costs as products near the loss of patent protection, diverging from a standard industry practice he admits the company has followed in the past.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.